Jordan Advances Global CAR-T Access with High-Efficiency Point-of-Care Manufacturing Using CliniMACS Prodigy

July 19, 2026

ASCO Publications Jordan

Overview

In a significant step towards democratizing advanced cell therapies, point-of-care manufacturing of anti-CD19.1 CAR-T cells using the Miltenyi CliniMACS Prodigy system was successfully demonstrated in Jordan. The process achieved an impressive 88.8% transduction efficiency and 267-fold T-cell expansion, with an efficient 15.25-day vein-to-vein time. This breakthrough underscores the potential for substantially reducing manufacturing costs and expanding global access to life-saving CAR-T treatments, particularly in underserved regions.

In Depth

Background

Chimeric Antigen Receptor (CAR-T) cell therapy has revolutionized the treatment of specific hematological malignancies, offering unprecedented clinical outcomes for patients with previously intractable cancers. However, the widespread adoption of CAR-T therapies is currently hampered by complex, expensive manufacturing processes that require highly specialized facilities and expertise. This limits their availability to a select few major medical centers globally, creating a particularly acute problem in developing countries and regions with constrained healthcare resources.

Point-of-care manufacturing emerges as a compelling solution to these challenges, enabling the production of therapeutic agents closer to the patient. This approach significantly reduces transportation costs and time, thereby facilitating faster treatment initiation. Automated, closed systems, such as the Miltenyi CliniMACS Prodigy, are pivotal in overcoming these logistical and cost barriers while simultaneously ensuring robust product quality and patient safety, thus paving the way for broader accessibility.

Key Findings

The feasibility of point-of-care manufacturing for anti-CD19.1 CAR-T cells using the Miltenyi CliniMACS Prodigy system has been successfully demonstrated in Jordan. This pioneering on-site production approach achieved a robust transduction efficiency of 88.8% and an impressive T-cell expansion rate averaging 267-fold. This significant achievement not only indicates a potential for substantial reduction in CAR-T therapy manufacturing costs but also promises to broaden geographical access to this life-saving treatment in regions where current availability is limited. The entire process, from cell collection to patient infusion, exhibited a highly efficient average vein-to-vein time of just 15.25 days.

Technical and Clinical Details

The study involved the processing of autologous peripheral blood mononuclear cells (PBMCs) within the integrated Miltenyi CliniMACS Prodigy system. This was followed by lentiviral transduction with the anti-CD19.1 CAR gene to engineer the T-cells. The cells were then automatically cultured and expanded within the closed system, yielding a final product that maintained high cell viability and functionality. Specifically, the final CAR-T cell product consistently demonstrated an average transduction efficiency of 88.8%, with T-cells expanding by an average of 267-fold. These results confirm that a standardized, automated, and closed-system approach can ensure high quality control and efficient manufacturing, even in environments with limited resources. Such a system is crucial for democratizing global access to CAR-T cell therapies and bridging existing healthcare disparities.

Strategic Significance and Outlook

This successful demonstration of point-of-care CAR-T manufacturing in Jordan represents a pivotal step towards expanding global access to advanced cell therapies. If similar decentralized manufacturing models are adopted and scaled in other regions, a significantly larger population of patients could benefit from this innovative therapeutic modality. Furthermore, the substantial reduction in manufacturing costs has the potential to enhance the overall sustainability of healthcare systems and accelerate the integration of CAR-T therapies into public health insurance schemes worldwide. In the long term, such decentralized manufacturing approaches could redefine the future of personalized medicine, potentially becoming the standard for cell therapy delivery globally, ensuring equitable access to cutting-edge treatments.

Source: https://ascopubs.org/doi/10.1200/GO-25-00648

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.